Trifluridine indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
==Indications | ==Indications and Usage== | ||
VIROPTIC Ophthalmic Solution, 1% (trifluridine ophthalmic solution) is indicated for the treatment of primary [[keratoconjunctivitis]] and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | publisher = |date = | accessdate = }}</ref> | VIROPTIC Ophthalmic Solution, 1% (trifluridine ophthalmic solution) is indicated for the treatment of primary [[keratoconjunctivitis]] and recurrent epithelial [[keratitis]] due to [[herpes simplex virus]], types 1 and 2.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 21:55, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
VIROPTIC Ophthalmic Solution, 1% (trifluridine ophthalmic solution) is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.